French pharmaceutical giant Sanofi announced on Monday that it is acquiring American biotech company Blueprint Medicines Corporation to strengthen its position in rare immunological diseases.
For this acquisition, Sanofi will pay $129 per share, representing a value of approximately $9.1 billion (more than €7.9 billion).
"Subject to the completion" of several clinical development and regulatory milestones, the total valuation could rise to $9.5 billion (€8.3 billion), according to the French group.
This acquisition "represents a strategic leap forward in our rare disease and immunology portfolios," said Paul Hudson, CEO of Sanofi, quoted in the press release.
Blueprint, a US-based, publicly traded biotech company, specializes in systemic mastocytosis, an orphan disease characterized by the abnormal activation or proliferation of cells called mast cells in tissues, most commonly the skin and bone marrow, which can, in the systemic form of the disease, damage organs.
The acquisition includes Ayvakit/Ayvakyt (avapritinib), the "only approved drug" for this rare disease, according to the press release.
The transaction "complements recent acquisitions of early-stage drugs, which remain our primary focus," Hudson continued.
On May 22, Sanofi announced the acquisition of Vigil Neuroscience, Inc., a biotechnology company specializing in the development of innovative drugs for the treatment of neurodegenerative diseases, for $470 million.
The acquisition of Blueprint "will not have a significant impact on Sanofi's financial guidance for 2025," the French group said.
English 
French